Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: FTSE flat, DAX (0.2%) CAC (0.2%), IBEX flat, MIB (0.1%)

Jun 16 ,2025

  • Synopsis

    • European equity markets set to open broadly flat to lower. Last week, European equity markets posted a notable negative performance, with Stoxx 600 declining to a three-week low, down over (1.5%) as risk appetite soured following an escalation in Middle East tensions. Strikes by Israel and Iran have continued as the conflict between the two countries intensifies. Iran launched a barrage of missiles at targets across Israel. The Iranian strikes came shortly after Israel launched attacks on surface-to-surface missile sites in Iran, and killed the intelligence chief of Iran's armed forces. (BBC)

    • Asian equities mixed to mostly lower Monday. China activity data mixed with industrial production and fixed asst investment growth slowing by more than expected. Retail sales an unexpected bright spot with growth highest since Dec-2023, aided by consumer goods trade-in program and early month holiday spending.

    • The week ahead sees Eurogroup meeting, several interest rate decisions (BOE, SNB, Norges Bank, BoJ and Fed), the Paris Airshow, Germany Jun ZEW survey, France Jun business confidence, UK May CPI/RPI as well as earnings/updates from Ashtead Group (AHT.LN), Berkeley Group Holdings (BKG.LN), and Colruyt Group (COLR.BB). Fresenius Medical Care (FME.GR) is holding a Capital Markets Day.

    • G7 summit underway in Canada. Canada will host leaders of Italy, US, France, Germany, UK and Japan in Kananaskis, Alberta. POLITICO writes that with rising tensions between Israel and Iran, peace still elusive in Ukraine and U.S. President Donald Trump's tariffs prompting a global trade war, there is a lot to talk about and plenty to disagree on.

    • European macro data releases out today include Italy May final CPI, Switzerland May PPI, Norway May trade balance

    • Also on today's agenda: Bundesbank's Nagel speech at 9:00CET at Frankfurt Euro Finance Summit and panellist at 18:00 at event at bank's Chemnitz branch. Also, the German central bank publishes at 12noon pre-releases from monthly report and ECB Economic Bulletin pre-release at 10:00CET. ECB's Cipollone speech at 12:30CET at Osservatorio Banca Impresa 2030 Meeting. OPEC monthly report is due for release whilst in Switzerland, SECO publishes its latest economic forecast. Elsewhere, there is the Paris Airshow (through Sun) and meeting of EU energy ministers.

    • On the corporate front, focus on reports Luca de Meo is leaving Renault (RNO.FP) to become Kering CEO (KER.FP). Renault's board has initiated the process of appointing a new CEO. In M&A, Spectris (SXS.LN) confirms receipt of preliminary acquisition proposal from KKR on 5-Jun-25; discloses board rejected proposal, no further proposal has been received at present. Pollen Street Capital offers to buy Metro Bank (MTRO.LN); terms unreported, according to Sky News.

  • Politics/Macro/World News

    • Iran rejects ceasefire negotiations while under Israeli attack, official says -- Reuters

    • Israel-Iran war crashes on to agenda at Canada's G7 summit -- FT

    • SNB Is Set to Cut to Zero But Shirk From Negative Rate for Now -- Bloomberg

    • UK Jun house price index +0.8% y/y vs prior +1.2%; (0.3%) m/m vs prior +0.6% - Rightmove

    • Economists Predict Germany Will Return to Growth This Year -- Bloomberg

  • Top company news

    • M&A

      • TEF.SM (Telefonica) -- agrees to sell Otecel S.A. (Telefónica Ecuador) to Millicom Spain, S.L. for $380M (post EU close on 13-Jun)

      • SXS.LN (Spectris) -- confirms receipt of preliminary acquisition proposal from KKR on 5-Jun-25; discloses board rejected proposal, no further proposal has been received at present

      • KKR (KKR & Co.) -- KKR signs deal to acquire Zenith Energy - Australian Financial Review

      • BT.A.LN (BT Group) -- AI advances could result in higher-than-expected job losses at BT Group - FT

      • BIM.FP (bioMerieux) -- bioMérieux announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company

      • RNO.FP (Renault) -- NIssan to sell portion of Renault stake - Nikkei, citing an interview with CEO Iván Espinosa

      • IP.IM (Interpump Group) -- agrees to acquire 65% of Padoan based on value of ~€16M for 100% of the company

      • MTRO.LN (Metro Bank Holdings) -- Pollen Street Capital offers to buy Metro Bank; terms unreported - Sky News

      • BGN.IM (Banca Generali) -- Mediobanca postpones shareholder meeting on Banca Generali from tomorrow to 25-Sep

      • ISB.IR (Íslandsbanki) -- announces that Kvika bank's board has rejected merger discussions

      • BURE.SS (Bure Equity) -- Bure enters into an agreement to acquire 17.0% of Silex Microsystems AB for total purchase price of SEK 917M

      • Blackstone in talks to buy Sunseeker Resort from Allegiant Travel Co - Bloomberg

      • Santos receives takeover from XRG-led consortium:

    • Healthcare

      • JNJ (Johnson & Johnson) -- presents new results from Phase 2 RedirecTT-1 study of TALVEY-TECVAYLI combination

      • REGN (Regeneron) -- Regeneron, Sanofi present results from EVEREST Phase 4 trial of Dupixent at EAACI Annual Congress

      • SRPT (Sarepta Therapeutics) -- Sarepta provides safety update on ELEVIDYS after second patient death; conference call at 08:00 ET 16-Jun

      • ROG.SW (Roche Holding) -- Follow-up: Roche announces new dosing restrictions, effective immediately, for Elevidys

      • ROG.SW (Roche Holding) -- Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

      • GMAB.DC (Genmab) -- announces new results from EPCORE NHL-2 trial Arm 10 evaluating epcoritamab combined with R-ICE

      • DIA.IM (Diasorin) -- FDA grants clearance of 510(k) for DiaSorin's LIASON MUREX HIV assay and control

      • EGTX.SS (Egetis Therapeutics) -- announces exclusive distribution agreement with Er-Kim for Emcitate in Türkiye

    • Other

      • KER.FP (Kering) -- Luca de Meo leaving Renault to become Kering CEO - Le Figaro

      • RNO.FP (Renault) -- CEO Luca de Meo to step down effective 15-Jul to pursue new challenges outside automotive sector

      • TTE.FP (TotalEnergies) -- UK commissions human rights review into $20B TotalEnergies gas development in Mozambique - FT

      • DSFIR.NA (DSM-Firmenich) -- Honeywell (HON) announces settlement with DSM-Firmenich; terms not reported

      • WCH.GR (Wacker Chemie) -- assesses its progress toward achieving its 2030 sustainability targets

      • Estimated weekend box office revenues in US, Canada $151.3M, (29.3%) y/y - Box Office Mojo

      • Slimmed down FDA ready to review infant formula - NY Times

  • Key rating changes

    • Upgrades

      • MNG.LN (M&G) -- to overweight from equal weight at Barclays

      • SYENS.BB (Syensqo) -- to buy from hold at Jefferies

      • UMI.BB (Umicore) -- to buy from hold at Jefferies

      • MTRO.LN (Metro Bank Holdings) -- to market perform from underperform at Keefe, Bruyette & Woods

    • Downgrades

      • ISS.DC (ISS A/S) -- to neutral from buy at UBS

      • AV.LN (Aviva) -- to equal weight from overweight at Barclays

      • AKE.FP (Arkema) -- to hold from buy at Jefferies

      • CLN.SW (Clariant) -- to hold from buy at Jefferies

      • BNR.GR (Brenntag) -- to underperform from hold at Jefferies

      • SY1.GR (Symrise) -- to underperform from hold at Jefferies

      • AED.BB (Aedifica) -- to hold from buy at Kepler Cheuvreux

      • SQN.SW (Swissquote Group) -- to sell from neutral at UBS

    • Other Actions

      • ELI.BB (Elia Group SA/NV) -- reinstated buy at Goldman Sachs

  • Data

    • Nikkei (0.89%) to 37834.25

    • Hang Seng (0.59%) to 23892.56

    • Shanghai Composite (0.75%) to 3377.00

    • S&P futures (1.0) vs prior close of 5979.3

    • €-$ +0.0028 or +0.24% to 1.1561

    • $-¥ +0.05 or +0.03% to 144.07

    • €-¥ +0.08 or +0.05% to 166.54

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE